Cargando…

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

BACKGROUND: The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health. The use of antiviral drugs in patients with this disease have triggered people’s attentions. Whether interferon alfa-2b or lopinavir/ritonavir (LPV/r) plus interferon alfa-2b treatment can agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jingyuan, Du, Chunjing, Pu, Lin, Xiang, Pan, Xiong, Haofeng, Xie, Wen, Chen, Zhihai, Li, Ang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404023/ https://www.ncbi.nlm.nih.gov/pubmed/34461841 http://dx.doi.org/10.1186/s12879-021-06595-6

Ejemplares similares

Interferon alfa-2b in the management of recurrent conjunctival papillomatosis
por: Singh, Manpreet, et al.
Publicado: (2016)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Relapsed ocular squamous surface neoplasia treated with topical interferon alfa-2b
por: Rocha-de-Lossada, Carlos, et al.
Publicado: (2020)

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
por: Sato, Izumi, et al.
Publicado: (2014)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
por: Huang, Yin-Qiu, et al.
Publicado: (2020)

The use of interferon-alfa in Behçet's disease: review of the literature
por: Kötter, I, et al.
Publicado: (2003)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Interferon alfa 2b intralesional vs 5 fluorouracilo en el tratamiento de la condilomatosis/
por: Silva Cañetas, Carmen Sofía del Socorro
Publicado: (1997)

Interferón alfa 2b intralesional vs 5 fluorouracilo en el tratamiento de la condilomatosis
por: Silva Cañetas, Carmen Sofía del Socorro
Publicado: (1997)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer
por: Quan, Walter, et al.
Publicado: (2013)

Resolution of Primary Acquired Melanosis with Atypia after Treatment with Topical Mitomycin C and Interferon Alfa-2b
por: Ghassemi, Fariba, et al.
Publicado: (2015)

Episcleritis in a patient with mucosal melanoma treated with interferon alfa-2b and radiotherapy: a case report
por: Yang, Li, et al.
Publicado: (2018)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
por: Levent, Görenek, et al.
Publicado: (2006)

Interferon alfa–induced sarcoidosis resolving without drug withdrawal
por: Ortiz Salvador, José María, et al.
Publicado: (2016)

Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1
por: Azamor, Tamiris, et al.
Publicado: (2021)

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease
por: Park, Ji-Youn, et al.
Publicado: (2015)

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa
por: Wang, Shaoyang, et al.
Publicado: (2011)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review
por: Gimeno-Carrero, Mónica, et al.
Publicado: (2021)

Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
por: Levesque, N., et al.
Publicado: (2008)

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
por: How, Joan, et al.
Publicado: (2020)

Interferon gamma and interleukin 1, but not interferon alfa, inhibit rotavirus entry into human intestinal cell lines
por: Bass, DM
Publicado: (1997)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
por: Taura, Naota, et al.
Publicado: (2012)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Pharmacists’ role in multidisciplinary diagnosis and treatment in adverse reactions: A case report of interferon alfa-2b induced severe lupus
por: Chen, Hongxia, et al.
Publicado: (2022)

Heterogeneity of treatment effect of interferon-β1b and lopinavir–ritonavir in patients with Middle East respiratory syndrome by cytokine levels
por: Arabi, Yaseen M., et al.
Publicado: (2022)

Production of a cellular product consisting of monocytes stimulated with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for human use
por: Green, Daniel S., et al.
Publicado: (2019)

Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
por: Kim, Gun-Wook, et al.
Publicado: (2013)

A Severe Case of Lymphomatoid Papulosis Type E Successfully Treated with Interferon-Alfa 2a
por: Bilgiç Temel, Aslı, et al.
Publicado: (2017)

Predictive Factors for Beneficial Response to Interferon-alfa Therapy in Chronic Hepatitis C
por: Yoon, Seung-Kew, et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_1cspq7bh6n2btvtie9n8bug5vo